Skip to content

Study of Tomotherapy in Patients With Benign Brain Tumour

A Phase I Study of Tomotherapy in Patients With Benign Brain Tumour

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00128986
Enrollment
49
Registered
2005-08-11
Start date
2005-05-31
Completion date
2014-08-31
Last updated
2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Neoplasms

Keywords

radiotherapy, brain

Brief summary

Although malignant brain tumors are the most common type of primary brain tumor, there are a number of other benign brain tumors that exist. Many difficulties exist with treating these tumors that have led to controversies in the best treatment. A common issue among these brain tumors is the risk of long term side effects from treatment. What limits the use of curative radiation therapy is the ability to deliver a maximal dose to the tumor while minimizing the amount of radiation to the normal structures in the brain. A new method of delivering radiation, called tomotherapy, has been acquired at the Cross Cancer Institute (CCI) and will be used in this study. It has the ability to deliver a high dose of radiation to the tumor while minimizing the amount of radiation to normal brain structures. This study will use this method of radiation therapy to deliver radiation and see if the long term side effects from radiation therapy can be reduced.

Interventions

PROCEDURETomotherapy

3T MRS scans (3T magnetic resonance spectroscopy)

Sponsors

AHS Cancer Control Alberta
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Histopathologically confirmed newly diagnosed base of skull benign tumour * Karnofsky Performance Status (KPS) equal to or greater than 70

Exclusion criteria

* Brain metastases or recurrent tumour * Prior radiotherapy (RT) to head or neck * No prior chemotherapy or radiosensitizer

Design outcomes

Primary

MeasureTime frame
safety and adverse effectsTrial Completion

Secondary

MeasureTime frame
efficacy and survivalTrial completion

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026